LSL Pharma Group

LSL Pharma Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of LSL Pharma Group (LSL.V) as of Nov 1, 2026 is 262.52 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -176.45 % — a change of -248.77% (higher).

FCF Conversion

262.52 %

YoY

-248.77%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of LSL Pharma Group is 2025 262.52 % . FCF Conversion Rate (FCF/EBITDA) of LSL Pharma Group was 2024 -176.45 % . It decreases by -248.77% higher compared to the previous year.

The LSL Pharma Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
-231.06 CAD
Jan 1, 2021
112.54 CAD
Jan 1, 2022
51.61 CAD
Jan 1, 2023
95.46 CAD
Jan 1, 2024
-176.45 CAD
Jan 1, 2025
262.52 CAD
The LSL Pharma Group FCF Conversion history
YEARFCF ConversionYoY
262.52 %-248.77%
-176.45 %-284.86%
95.46 %+84.95%
51.61 %-54.14%
112.54 %-148.70%
-231.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

LSL Pharma Group Stock analysis

What does LSL Pharma Group do? LSL Pharma Group, Inc. generates revenue through the development, manufacturing, and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The company operates as a pharmaceutical entity specializing in these specific therapeutic and wellness categories to meet market demand. The firm utilizes its subsidiaries, including Steri-Med Pharma Inc., LSL Laboratory Inc., and Groupe Immobilier LSL inc., to support its core operations. These entities facilitate the company's ability to produce and distribute its specialized pharmaceutical and supplement offerings effectively within its operational framework. LSL Pharma Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LSL Pharma Group stock

FCF Conversion Rate (FCF/EBITDA) of LSL Pharma Group is 262.52 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of LSL Pharma Group changed from -176.45 % to 262.52 %, representing a -248.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) LSL Pharma Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s LSL Pharma Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — LSL Pharma Group

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — LSL Pharma Group